Figure 4. Pharmacological inhibition of CB1R does not alter scaling up of synaptic activity by chronic TTX treatment, but blocks the suppressive effect of endogenous 2-AG on TTX- increased frequency of mEPSCs.

(a) Representative recording traces of mEPSCs under various treatments. The level of endogenous 2-AG was raised by inhibition of MAGL with JZL184 (2 μM). (b) Cumulative probability of mEPSC frequency recorded in neurons with different treatments (left) and mean percentage of changes in the frequency of mEPSCs in neurons with different treatments (right). (c) Cumulative probability of mEPSC amplitude recorded in neurons with different treatments (left) and mean percentage of changes in the amplitude of mEPSCs in neurons with different treatments (right). Data are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, compared with the control; ^##p < 0.01, ^###p < 0.001, compared with JZL184 (the Dunn’s post hoc test following the Kruskal-Wallis test).